Analysis of anticoagulants for blood-based quantitation of amyloid β oligomers in the sFIDA assay.
Early diagnostics at the preclinical stage of Alzheimer's disease is of utmost importance for drug development in clinical trials and prognostic guidance. Since soluble Aβ oligomers are considered to play a crucial role in the disease pathogenesis, several methods aim to quantify Aβ oligomers in body fluids such as cerebrospinal fluid (CSF) and blood plasma. The highly specific and sensitive method surface-based fluorescence intensity distribution analysis (sFIDA) has successfully been established for oligomer quantitation in CSF samples. In our study, we explored the sFIDA method for quantitative measurements of synthetic Aβ particles in blood plasma. For this purpose, EDTA-, citrate- and heparin-treated blood plasma samples from five individual donors were spiked with Aβ coated silica nanoparticles (Aβ-SiNaPs) and were applied to the sFIDA assay. Based on the assay parameters linearity, coefficient of variation and limit of detection, we found that EDTA plasma yields the most suitable parameter values for quantitation of Aβ oligomers in sFIDA assay with a limit of detection of 16 fM.
Kateryna
K
Kravchenko
Andreas
A
Kulawik
Maren
M
Hülsemann
Katja
K
Kühbach
Christian
C
Zafiu
Yvonne
Y
Herrmann
Christina
C
Linnartz
Luriano
L
Peters
Tuyen
T
Bujnicki
Johannes
J
Willbold
Oliver
O
Bannach
Dieter
D
Willbold
D000544:Alzheimer Disease / Q000175:diagnosis; D016229:Amyloid beta-Peptides / Q000097:blood*; D000925:Anticoagulants / Q000737:chemistry*; D001774:Blood Chemical Analysis / Q000379:methods*; D005453:Fluorescence; D006801:Humans; D012015:Reference Standards
D016229:Amyloid beta-Peptides; D000925:Anticoagulants